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Abstract
Background: Serum and urine metabolites have been investigated for their use as cancer biomarkers. The specificity
of candidate metabolites can be limited by the impact of other disorders on metabolite levels. In particular, the
increasing incidence of obesity could become a significant confounding factor.
Methods: Here we developed a multinomial classifier for the stratification of cancer, obesity and healthy phenotypes
based on circulating glucose and formate levels. We quantified the classifier performance from the retrospective analysis
of samples from breast cancer, lung cancer, obese individuals and healthy controls.
Results: We discovered that circulating formate levels are significantly lower in breast and lung cancer patients than in
healthy controls. However, the performance of a cancer classifier based on formate levels alone is limited because
obese patients also have low serum formate levels. By introducing a multinomial classifier based on circulating glucose
and formate levels, we were able to improve the classifier performance, reaching a true positive rate of 79% with a false
positive rate of 8%.
Conclusions: Circulating formate is reduced in HER2+ breast cancer, non-small cell lung cancer and highly obese patients
relative to healthy controls. Further studies are required to determine the relevance of these observations in other cancer
types and diseases.
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Background
Serum and urine biomarkers can enable the widespread
deployment of disease screening. A successful example
is the use of fasting serum glucose levels to diagnose dia-
betes [1]. In the context of cancer, several studies have
been conducted with the aim of identifying serum or
urine metabolites that could distinguish cancer patients
from healthy controls [2–5]. Within the range of meta-
bolites analysed in previous studies, no single metabolite
alone can be used to discriminate between samples
from cancer patients and healthy controls in a reliable
manner. Instead, complex metabolites signatures are
devised. The general consensus from these studies is
that a cancer diagnostic test based on a single meta-
bolite, mechanistically linked to cancer metabolism, is
not feasible.
Yet, we have previously observed that tumour-bearing
mice have high serum formate levels relative to matched
controls [6]. We therefore hypothesised that formate
levels could be utilised to screen for cancer disease in
the human population. To test this hypothesis, we per-
formed metabolite analysis of serum/plasma samples
from a Spanish cohort of breast cancer patients, lung
cancer patients, obesity patients and healthy controls. In
contrast to our observations in mice, circulating formate
levels are significantly lower in cancer patients than in
healthy controls. Formate levels were also found signifi-
cantly lower in patients with obesity, forcing us to
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concomitantly stratify obesity and cancer patients from
healthy controls. By introducing a multinomial classifier
based on glucose and formate levels, we were able to im-
prove the classifier performance, reaching a true positive
rate of 79% with a false positive rate of 8%.
Methods
Participants
We included plasma samples from 80 patients with severe
obesity (i.e., body mass index [BMI] > 40 kg/m2) enrolled
in an on-going study aimed to establish the prevalence of
non-alcoholic steatohepatitis (NASH). Patients were cate-
gorised according to the presence (n = 45) or absence
(n = 35) of type 2 diabetes mellitus (T2DM) as defined by
levels of fasting plasma glucose > 7.0 mmol/L and
HbA1c > 48 mmol/mol (6.5%). Patients were excluded if
aged < 25 years and self-reported alcohol consumption
was higher than 25 g/day or conflicted with the assess-
ment by relatives. Other exclusion criteria included posi-
tive values in markers indicative of autoimmune hepatitis,
hepatitis B or hepatitis C, and patients with a history of
cardiac disease, liver disease of non-metabolic aetiology,
current infections, chronic inflammatory diseases or
cancer. For comparisons, we used bio-banked samples
(n = 50) of healthy non-obese controls from a previous,
unrelated population study. Non-alcoholic fatty liver
disease (NAFLD) and T2DM were discarded via ultra-
sound and laboratory data obtained in health checkups,
that is, non-NAFLD, non-diabetic controls, using a
population-based approach.
We prospectively collected fasting plasma samples
(n = 58) of patients (84% male) with unresectable locally
advanced non-small cell lung cancer before chemoradio-
therapy. Patients were excluded if they presented with
metastatic disease or previous oncologic intervention.
All patients underwent staging with PET/CT imaging,
IIIA or IIIB in a 50/50 proportion. Mediastinum staging
also required endobronchial ultrasound or a mediasti-
noscopy approach in a significant number of patients.
All patients had a brain assessment by MRI. Tumour
histology revealed adenocarcinoma in 31 patients and
squamous cell carcinoma in 20. Before treatment, all
patients had an excellent (0–1) ECOG-PS score (Eastern
Cooperative Oncology Group performance status).
T2DM was present in 16 patients, hypertension in 19,
moderate-to-high consumption of alcohol in 31%, and
50% were current smokers. Written informed consent
was obtained from all participants as required by the
ethics committee of the Hospital Universitari Sant Joan
de Reus (Reus, Spain).
We also prospectively collected serum samples (n = 68)
from patients with early, non-metastatic HER2-positive
breast cancer that was recruited into the METTEN
study (EU Clinical Trials Register, EudraCT number
2011-000490-30; registered on 28 February 2011, https://
www.clinicaltrialsregister.eu/ctr-search/trial/2011-000490-
30/ES) [7]. Patients were eligible if they met the following
criteria: previously untreated, operable, locally advanced,
inflammatory breast cancer > 2.0 cm in the largest clinical
diameter and confirmed HER2 positivity (either immuno-
histochemistry 3+ or 2+ and positive for fluorescent or
chromogenic in situ hybridization). Other inclusion
criteria were age 18–75 years, baseline ECOG-PS score of
0 or 1 and baseline left ventricular ejection fraction ≥ 50%
measured by echocardiography or multiple gated acquisi-
tion scan; normal organ and bone marrow function (abso-
lute neutrophil count ≥ 1500/μL, platelets ≥ 100,000/μL,
total bilirubin ≤ 1.5× the upper limit of normal [ULN],
serum creatinine ≤ 1.5× ULN, AST and ALT ≤ 2.5× ULN);
ability to swallow and retain oral medication and blood
glucose levels ≥ 70mg/dL (3.9mmol/L). Patients were
excluded from this study if they had impaired cardiac
function (e.g. uncontrolled or symptomatic angina, clinic-
ally significant arrhythmias, congestive heart failure, trans-
mural myocardial infarction); uncontrolled hypertension;
concurrent treatment with therapies that can alter insulin
levels (including chronic treatment with oral corticoids);
and metabolic disease (e.g., T1/2 DM, obesity [BMI > 30
kg/m2]; impaired glucose tolerance [> 128mg/dL], hyper-
cholesterolaemia or hypertriglyceridaemia of grade ≥ 3
according to CTC-NCIC version 4.0). Other exclusion
criteria were metastatic disease; bilateral breast cancer;
any prior treatment for breast cancer; other malignancies
or less than 10 years from prior malignancies (except cura-
tively treated basal cell carcinoma, squamous cell carcin-
oma of the skin or carcinoma in situ of the cervix);
inadequate renal function (creatinine clearance < 60mL/
min); impaired liver function; enolism (average consump-
tion of 3 alcoholic beverages/day); significant dementia;
altered mental status (or any psychiatric condition that
would prohibit the understanding or rendering of in-
formed consent); pregnancy; and lactation. The ethics
committee of the Dr. Josep Trueta Hospital (Girona,
Spain) and independent Institutional Review Boards at
each site participating in the METTEN study approved
the protocol and any amendments. All procedures were
in accordance with the ethical standards of the institu-
tional research committees and with the 1964 Helsinki
Declaration and its later amendments or comparable
ethical standards. Informed consent was obtained from all
individual participants included in the METTEN study.
In all participants, venous blood was collected, after an
overnight fast, into sodium EDTA-containing tubes
(plasma) or into tubes with no anticoagulants added
(serum). The tubes were centrifuged at 2500×g at 4 °C,
and plasma or serum was stored at − 80 °C until used to
minimise preanalytical errors.
Pietzke et al. Cancer & Metabolism             (2019) 7:3 Page 2 of 11
Formate quantification
Formate was quantified by gas chromatography–mass
spectrometry (GC-MS) (Agilent) as described previously
[8]. Briefly, 40 μL of the samples were mixed with 20 μL
of internal standard (d2-formate, 50 μM), 10 μL of
NaOH (1 N), 50 μL of pyridine and 5 μL of benzyl alco-
hol. Derivatisation was performed by adding 20 μL of
methyl chloroformate while vortexing. After addition of
100 μL of methyl tertiary butyl ether and 200 μL H2O
followed by vortexing for 10 s and centrifugation (10 min
at max g), the apolar phase was transferred to a GC-vial
and capped. Blank samples (water) and formate stan-
dards with known concentration were prepared in a
similar manner and measured with the samples to sub-
tract background and validate the quantification. Peak
areas for formate and d2-formate were extracted and
processed with MassHunter Quantitative analysis soft-
ware (version B.06.00—Agilent Technologies). Quantifi-
cation was performed by comparing the peak area of
formate (m/z of 136) against that of d2-formate (m/z = 138)
after correcting for background signals. Because of the
high number of samples, we measured them in blocks,
but each block contained every sample type and sam-
ples were randomised within each block. Each block of
samples also included reference samples that were used
as quality controls. Additional file 1: Figure S1 shows
the measured formate values for these samples relative
to the spiked labelled formate in those references. The
data demonstrates the good quality of the formate quanti-
fication in the range 0–100 μM formate, which corre-
sponds to the readouts observed in human serum samples.
Targeted liquid chromatography–mass spectrometry
quantification
Other metabolites were measured as previously de-
scribed [9], with the extraction slightly modified to pre-
vent clogging of the column. Both plasma and serum
samples were diluted 1:100 in extraction solution
(methanol to acetonitrile to water [5:3:1 v/v]), followed
by a vortexing step and 10min shaking at 4 °C. Samples
were then centrifuged (max g, 10 min, 4 °C), transferred
to a new Eppendorf tube and stored overnight at − 80 °C.
After defrosting for 10min on ice, samples were
centrifuged a second time (max g, 10min, 4 °C), trans-
ferred to liquid chromatography (LC)-vials, separated on a
ZIC-pHILIC column and analysed with a Q-Exactive-orbi-
trap MS (Thermo Fisher). As a quality control for the
LC-mass spectrometry (LC-MS) quantification, we spiked
in a 13C- and 15N-amino acid mixture. (Additional file 1).
The quantified amino acid concentrations were found
in a range previously reported for human serum [10]
(Additional file 1: Table S2 and Figure S2). Using
amino acids as quality controls, we identified matrix
effects due to co-elution with EDTA in all plasma samples
(Additional file 1: Figures S3–S6).
Relative mutual information
The mutual information of a classifications system S*
relative to a reference system S is calculated as








where U is the set of all samples considered in the
study, pab is the fraction of individuals that belong to
class a and b in the classification systems S and S*,
respectively, qa is the fraction of individuals that belong
to class a in the classification system S and rb is the
fraction of individuals that belong to class b in the classi-
fication system S*. The relative mutual information is
defined here as the mutual information normalised to its
maximum attainable value when S* = S,







We consider the sets H, C and O as containing the samples
of healthy controls, cancer patients and obesity patients,
respectively, as provided in the reference annotation. We
also consider the sets H*, C* and O* as containing the
samples imputed as healthy controls, cancer patients and
obesity patients, respectively, based on a given classi-
fier. As indicated above, U is the set of all samples. A
training set (T ⊂U) or a validation set (V ⊂U) are also
defined depending on whether we are performing a re-
ceiver operating characteristic (ROC) study or a cross-
validation analysis, as described below. The training set
is used to determine the optimal parameters of the classi-
fier. The validation set is used to quantify the TPR and FPR
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where X∩Y denotes the intersection between X and Y
(elements common to X and Y), |X| denotes the size of
X (number of elements in X), and pO is the obesity
prevalence in the population. The generalisation of this
equation for more than two diseases is straightforward
and reported in the Additional file 1.
Pietzke et al. Cancer & Metabolism             (2019) 7:3 Page 3 of 11
Receiver operating characteristic plots
In this case, both the training and validation sets contain
all samples (T=V=U). The ROC plots were generated by
changing FT or (GT,FT) across all observed values. For
each threshold, we classified every sample in the vali-
dation set and determined the true and false positive
rate (TPR and FPR, respectively).
Cross-validation
For each realisation of the cross-validation procedure,
each sample in the study was assigned to a training set
(T) with probability 0.75 or to a validation set (V) other-
wise. Results were averaged over 100,000 realisations of
(T,V). For each quantity of interest, the values separating
the 5, 50 (median) and 95% lower values from the
remaining higher values were calculated. The results are
then reported as median (5–95% values).
F-classifier validated in H + C
The imputed classes (S*) are determined as
Si FTð Þ ¼
c if Fi < FT
h Otherwise

where Fi denotes the serum formate level of sample i
and FT is a predefined threshold. The best formate
threshold was calculated as
F0 = arg max i(S, S
∗(FT)|V ∩ (H ∪C))
C* and H* were defined as the set of all samples
imputed by the F0-classifier as having cancer or being
healthy, respectively. The validation is conducted setting
the obesity prevalence to zero (pO = 0). In this case, the
obesity class is irrelevant.
F-classifier validated in H + C + O
Proceeds as described above, but the obesity prevalence
is set to 20% (pO = 0.2).
(G,F)-classifier validated in H + C + O
The imputed classes (S*) are determined as
Si GT ; FTð Þ ¼
o ifGi > GT




where Gi denotes the serum glucose level of sample i
and GT is a predefined threshold. The best formate
threshold was calculated as
ðG0; F0Þ ¼ arg max
ðGT ;FT Þ
i ðS; SðGT ; FT ÞjV∩ðH ∪C∪OÞÞ
where C*, O* and H* were defined as the set of all
samples imputed by the (G0,F0)-classifier as cancer,
obesity or healthy, respectively. The obesity prevalence is
set to 20% (pO = 0.2).
Results
Our goal was to develop a classifier that differentiates
cancer and healthy samples based on circulating metab-
olite levels. We followed a standard case-control study
where biological samples were obtained from patients
with a given disease and from healthy controls (Fig. 1a).
The disease of interest was cancer and the biological
samples were serum from women with HER2/Erb2-posi-
tive primary breast cancer, plasma from non-small cell
lung cancer patients and plasma from healthy controls
(Table 1). Mechanistic studies (e.g. animal models) can
inform the choice of metabolites to be screened; a good
example is blood glucose in the context of diabetes [1].
In the context of cancer, we previously reported that
tumour-bearing mice have high serum levels of formate
relative to matched controls [6]. We therefore hypo-
thesised that formate levels could be used to screen for
cancer in the human population.
We quantified circulating formate in the biological
samples using a gas chromatography–mass spectrometry
(GC-MS) protocol [8]. In contrast to our previous obser-
vations in mice, circulating formate levels were signifi-
cantly lower in breast and lung cancer patients than in
healthy controls (Fig. 1b). To compare the discriminative
power of formate relative to that of other metabolites,
we quantified the levels of a broad spectrum of metabo-
lites using LC-MS. Among the metabolites quantified,
formate showed the highest fold reduction in breast and
lung cancer relative to healthy control samples (Fig. 1c,
d and Additional file 1: Table S1). We found only three
metabolites with a consistent and significant change be-
tween each cancer type and healthy controls: formate,
glutamate and sarcosine. The fold change of glutamate
was, however, small compared with that observed for
formate. Sarcosine exhibited a fold change similar to that
of formate, but its levels were highly correlated with
those of formate (Pearson correlation 0.60, p = 10−6,
permutations test).
F-classifier
These observations encouraged us to develop a cancer
classifier using circulating formate levels as input. Spe-
cifically, samples were imputed as cancer if formate
levels were below a predefined threshold (FT) and as
healthy (or no cancer) otherwise. Changing the formate
threshold, we obtained an excellent ROC curve (Fig. 1e),
with a TPR close to 100% almost independently of the
FPR. The classifier also performed well in a cross-valid-
ation analysis, where 75% of the cancer and healthy sam-
ples were used to estimate the best FT and the remaining
25% of samples were used for validation (Fig. 1e, blue
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circle). Taking an average of over 100,000
cross-validations, we obtained a TPR of 90% (82–97%)
and an FPR of 8% (0–25%). Based on this standard
case-control analysis, we conclude that formate alone can
be used to screen for cancer in the human population.
In the clinical setting, we would encounter patients
with cancer and healthy controls and individuals with
other underlying diseases as well. Of particular relevance
is obesity, which is estimated prevalence at 11–15% glo-
bally and is projected to reach 20% in 2025 [11]. To in-
vestigate the impact of obesity in the performance of the
formate-based classifier, we expanded the cohort to in-
clude plasma samples from patients with obesity (Table 1)
and the levels of formate and other metabolites were
quantified. We then repeated the cross-validation analysis
including obesity samples in the validation cohort, at a
rate of 20% per healthy control (Fig. 1e, red square). With
the inclusion of obesity in the validation cohort, the FPR
increased significantly to 17% (9–31%) (Fig. 1e, red square
vs blue circle, p = 10−5, Welch test). These observations il-
lustrate how a biomarker may seem to perform quite well
in a single disease (e.g. cancer) and healthy control study.
Yet, the classifier’s performance deteriorates when tested
in the human population, due to the prevalence of other
diseases affecting the biomarker (e.g. obesity). To over-
come this caveat, we transformed the study design from a
single disease and healthy controls (Fig. 1a) to multiple
diseases and healthy controls (Fig. 2a). The key develop-
ment is a validation set representing the relevant dis-
eases that may be encountered in the human
population. By relevant, we mean those diseases with
similar biomarker profiles that may confound the
Fig. 1 Formate classifier. a Schematic representation of a standard case-control study to identify and validate disease metabolite biomarkers.
b Box plots of serum formate levels across healthy controls (H), HER2+ breast cancer (BC) and non-small cell lung cancer (LC) samples. Each
point represents a sample, the error bars indicate the range excluding the lowest 5% and highest 5% values, boxes the range excluding the
lowest 25% and highest 25% values, and the line within the box the median. Asterisk/double asterisks denote a significant difference of 10−3/10−6
relative to healthy controls (−), two-tailed t test with unequal variance. c, d Volcano plots reporting the statistical significances vs fold change of
metabolite levels relative to the healthy controls, in BC (c) and LC (d). Each point represents a metabolite and selected metabolites are indicated by
their abbreviated name. e ROC plot for the formate-based classifier (brown line), together with the FPR and TPR obtained from cross-validations not
corrected (CV) and accounting (CV corrected) for obesity incidence The symbol reports the median and the error bars the observed range excluding
the 5% lowest and largest values
Table 1 Characteristics of the study population
H BC LC OD− OD+
n = 50 n = 68 n = 56 n = 46 n = 35
Age 48 ± 14 48 ± 11 66 ± 9 50 ± 10 42 ± 12
BMI 27 ± 6 25 ± 3 27 ± 5.1 46 ± 7 51 ± 9
H healthy controls, BC early stage non-metastatic HER2+ breast cancer patients
before treatment, LC unresectable locally advanced non-small cell lung cancer
patients before chemoradiotherapy, OD− severe obesity patients without
T2DM, OD+ severe obesity patients with T2DM. Values are reported
as mean ± SD
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discrimination between them. This also entails a change
in the methodology from a binomial classifier (positive
or negative) to a multinomial classifier (disease A, di-
sease B,…, healthy).
To demonstrate the feasibility of this multinomial
approach, we used the simultaneous diagnosis of cancer
and obesity as a case study. In obesity, patient formate
levels span a range from those observed in healthy indi-
viduals to those seen in cancer patients (Fig. 2b), which
limits the use of a classifier for cancer based solely on
formate levels. Indeed, a subset of patients with obesity
presented formate levels as low as those observed in
cancer patients. Accordingly, to address the issue of
identifying cancer patients using serum formate, we have
to discriminate additionally between cancer and obesity.
In agreement with previous evidence [1], glucose levels
are increased in patients with obesity relative to controls,
independently of whether or not these patients have
diabetes (Fig. 2c). As anticipated, glucose was among the
metabolites with the highest fold increase in obesity
patients with or without diabetes relative to healthy
controls (Fig. 2d, e). By contrast, glucose levels were
not significantly different between cancer patients and
healthy controls (Fig. 2c).
(G,F)-classifier
Based on these observations, we designed the following
decision tree classifier. First, the samples were classified
as obesity (glucose >GT) or other (glucose <GT), where
GT is a predefined glucose threshold. Subsequently, the
other group was stratified based on formate levels into
cancer (formate < FT) or healthy (formate > FT), where
FT is a predefined formate threshold. We first varied
(GT,FT) over the range of observed glucose and formate
levels. For a given (GT,FT), we classified all samples and
determined the relative mutual information, i(S*,S),
between the classifier status prediction (S*) and the
actual status (S). The relative mutual information mea-
sures the similarity between two classification systems.
i(S*,S) takes the maximum value 1 when the classifier has
a perfect match with the actual status (S* = S) and is zero
when the classifier predictions are uncorrelated from the
actual status. Figure 3a shows i(S*,S) as a heatmap in the
(GT,FT) plane. The highest relative mutual information is
Fig. 2 (Glucose,Formate) classifier. a Schematic representation of the proposed study design to identify and validate disease metabolite biomarkers
considering the prevalence of multiple diseases. Box plots of formate (b) and glucose (c) levels across the healthy controls (H), HER2+ breast cancer
(BC), non-small cell lung cancer (LC), severe obesity without diabetes (OD−) and severe obesity with diabetes (OD+) samples. Each point represents a
sample, the error bars indicate the range excluding the lowest 5% and highest 5% values, boxes the range excluding the lowest 25% and highest 25%
values, and the line within the box the median. Asterisk/double asterisks denote a significant difference of 10−3/10−6 relative to healthy controls (−),
two-tailed t test with unequal variance. d, e Volcano plots reporting the statistical significances vs fold change of metabolite levels in the indicated
group relative to the healthy controls, in OD+ (d) and OD- (e). Each point represents a metabolite and selected metabolites are indicated by the labels
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obtained for GT = 1.3 × 10
8 (peak area) and FT = 0.054
mM, resulting in i(S*,S) = 0.36 (p = 10−5, permutation test,
105 permutations). Figure 3b reports the distribution of
the serum samples profiled with the (GT,FT), colour coded
by status. The lines separate the (GT,FT) plane into diffe-
rent regions based on the optimal values of the aforemen-
tioned GT and FT. From the visual inspection of this
figure, it can be concluded that the classifier performs well
at separating the different groups.
We next performed an ROC analysis of the (GT,FT) clas-
sifier to quantify its performance in terms of TPR and
FPR. Given that we have two disease classes, cancer and
obesity, we determined these quantities focusing either on
cancer as the positive event and the remainder as negative,
or on diabetes as the positive event and the remainder as
negative. We note that the ROC plot associated with
two or more biomarkers is generally a surface in the
(FPR,TPR) plane (Fig. 3c). The ROC plot for cancer
demonstrates that the cancer classifier can reach a TPR
above 80% with an FPR below 20% (Fig. 3c). We also
performed a cross-validation analysis where 75% of the
samples were used for training and the remaining 25%
samples were used for validation, after correcting for the
obesity prevalence. The training set was used to determine
the choice of (GT,FT) maximising i(S*,S) and the validation
set was used to estimate the TPR and FPR. Taking an
average of over 100,000 cross-validations, we obtained a
TPR of 79% (63–92%) and an FPR of 23% (12–37%), for
the cancer classifier (Fig. 3c, red square).
The performance of the classifiers discussed above is
compared side-by-side in Figs. 3d, e. The TPR of the
F-classifier was not affected by the inclusion of obesity
patients in the validation cohort (Fig. 3d, blue vs black).
By contrast, the FPR increased when the F-classifier is
Fig. 3 Performance of the (Glucose,Formate) classifier. a Colour map of the relative mutual information between the classifier prediction and the
reference classification as a function of the formate and glucose thresholds. b Scatter plot of human serum samples as a function of the formate
and glucose concentrations, colour coded by the sample subtypes. The horizontal and vertical lines represent the best glucose and formate
threshold, respectively. c ROC plot for the glucose + formate-based classifier, focusing on the cancer class. The brown area reports the FPR and
TPR for different formate and glucose thresholds and the red symbol the corresponding cross-validation values (symbol for median and error
bars for observed range excluding the 5% lowest and largest values). d, e Comparison of the different classifiers according to their TPR (d) and
FPR (e). Corrected indicates accounting for obesity incidence. Error bars indicate the range excluding the lowest 5% and highest 5% values,
boxes the range excluding the lowest 25% and highest 25% values, and the line within the box the median
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validated in a cohort including obesity patients, which is
closer to what is expected in the clinical context (Fig. 3e,
blue vs black). This increase in FPR is corrected by the
(G,F) classifier, as a result of the inclusion of glucose as
a biomarker to impute obesity (Fig. 3e, red vs black).
This improvement comes at the expense of a reduction
in the TPR (Fig. 3d, red vs black) because a small frac-
tion of the cancer patients is imputed as belonging to
the obesity class. These are the blue and green symbols
above the horizontal line in Fig. 3b.
Cancer-type-specific metabolites
As discussed above, formate, sarcosine and glutamate
exhibit differences in the same direction when com-
paring breast or lung cancer with healthy controls.
There are also metabolites showing cancer-type-specific
changes (Additional file 1: Table S1). Sarcosine itself is
significantly lower in breast cancer than in all other
groups, including lung cancer (Fig. 4a). By contrast,
serine, aspartate and arginine are significantly higher
in breast cancer as compared with all other groups
(Fig. 4b–d). In the case of lung cancer, pyruvate is
higher and threonine is lower than in the breast cancer,
but not significantly different from the obesity samples
(Fig. 4e, f ). These metabolites could be exploited to fur-
ther stratify the cancer samples into breast or lung cancer.
However, we cannot fully address their relevance within
this work. We are lacking a quantification of their levels in
other cancer subtypes such as brain, blood, colorectal and
ovarian cancers, which have an incidence comparable with
that of breast and lung cancers.
Discussion
This analysis indicates that formate is a promising
biomarker for cancer diagnosis. To address the rele-
vance of formate in a wider context, we searched the
scientific literature for previous studies measuring cir-
culating formate in clinical samples and healthy con-
trols or in animal models of human disease (Table 2).
In most investigations, formate was quantified using
nuclear magnetic resonance (NMR), except for one
case utilising an enzymatic method. A study in rhesus
monkeys reported significantly lower levels of formate
in animals with type 2 diabetes than in matched con-
trols [12]. In an investigation of patients with colorec-
tal cancer in Denmark, it was noted that obese
patients had significantly lower serum formate levels
than non-obese controls [13]. These studies support
Fig. 4 Cancer type specific metabolites. Box plots of metabolite levels manifesting a significant difference between breast or lung cancer and the
other groups. The sample groups include healthy controls (H), HER2+ breast cancer (BC), non-small cell lung cancer (LC), severe obesity without
diabetes (OD−) and severe obesity with diabetes (OD+) samples. Each point represents a sample, the error bars indicate the range excluding the
lowest 5% and highest 5% values, boxes the range excluding the lowest 25% and highest 25% values, and the line within the box the median.
Asterisk/double asterisks denote a significant difference of 10−3/10−6 relative to BC (a–d) or LC (e, f), two-tailed t test with unequal variance
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our observation of lower serum formate levels in
obese individuals.
In the context of cancer, we found reports of both low
or high serum formate depending on the cancer type.
Patients with lung cancer [14, 15] or hepatocellular car-
cinoma [16] are characterised by lower serum levels of
formate, whereas formate is found significantly higher in
the serum of patients with colorectal [13, 17] and blood
[18] cancer. It seems there is a subset of cancers with
lower serum formate levels than in healthy controls (e.g.
lung and breast) and another subset of cancers where
serum formate levels are higher than in healthy controls
(e.g. colorectal). These observations are in line with the
current view that different cancer types may represent
different metabolic phenotypes.
It is unclear why there is a dichotomy of formate levels in
cancer relative to healthy controls. Interestingly, those
cancers exhibiting lower serum formate (breast and lung)
are among those where increased cell proliferation is a
marker of poor prognosis. By contrast, colorectal cancer,
showing high serum formate, is among those where
increased tissue remodelling is a marker of poor prognosis
[19]. Increased cell proliferation and tumour growth could
drive the depletion of endogenous sources of one-carbon
units, which sustain the biosynthesis of nucleotides [20, 21].
The oxidative or reductive nature of the cancer could be a
relevant factor. Data from mouse models indicate that
cancers with high oxidative metabolism are associated with
increased serum levels of formate [6]. However, we
observed low formate levels in the serum of human lung
cancer patients, and human lung cancer can be of oxidative
nature [22]. Other factors such as alterations in liver func-
tion, the immune system and the gut microbiome cannot
be excluded.
Finally, we found reports of increased serum formate
levels in patients with inflammatory diseases (ulcerative
colitis and Crohn’s disease [23]) and neurological diseases
(amyotrophic lateral sclerosis [24] and Parkinson’s disease
[25]) relative to healthy controls. Thus, the use of serum
formate as a potential biomarker for cancers with high
serum formate will need further consideration. Indeed, we
would need additional biomarkers to discriminate between
Table 2 Studies reporting formate measurements in humans and primates
Study/condition Country Sample Assay Cases Controls Formate Fold change Significance Ref
Death vs asymptomatic/methanol poisoning Czech Republic Serum Enzymatic 6 15 ↑ 8 4.0E−3 [26]
Amyotrophic lateral sclerosis India Serum NMR 30 25 ↑ NR < 0.001 [24]
Parkinson’s disease vs healthy India Serum NMR 17 22 ↑ 3 < 0.001 [25]
Crohn’s disease Canada Serum NMR 20 40 ↑ NR < 0.05 [23]
Ulcerative colitis Canada Serum NMR 20 40 ↑ NR < 0.05 [23]
Non-Hodgkin’s lymphoma Poland Serum NMR 26 31 ↑ 1.7 < 0.05 [18]
Chronic lymphocytic leukaemia Poland Serum NMR 21 31 ↑ 1.5 < 0.05 [18]
Acute myeloid leukaemia Poland Serum NMR 38 31 ↑ 2.0 < 0.05 [18]
Colorectal cancer vs healthy China Othera NMR 127 43 ↑ NR 1.0E−3 [17]
Colorectal cancer vs healthy Denmark Serum NMR 153 139 ↑ 1.2 1.5E−5 [13]
Colorectal cancer vs healthy China Serum NMR 28 55 – NR > 0.05 [27]
Chronic pancreatitis vs healthy China Plasma NMR 20 20 ↑ NR < 0.05 [28]
Pancreatic cancer vs healthy China Plasma NMR 19 20 – NR > 0.05 [28]
Hepatocellular carcinoma European Serum NMR 114 222 – NR > 0.05 [29]
Hepatocellular carcinoma China Serum NMR 24 60 – 0.25 > 0.05 [30]
Hepatocellular carcinoma China Serum NMR 43 18 ↓ 0.07 < 0.05 [16]
Liver cirrhosis China Serum NMR 42 18 ↓ 0.36 < 0.05 [16]
Hepatocellular carcinoma vs liver cirrhosis China Serum NMR 43 42 ↓ 0.20 < 0.001 [16]
Lung cancer vs healthy China Serum NMR 39 43 – 0.87 > 0.05 [31]
Lung cancer vs healthy Portugal Plasma NMR 85 78 ↓ 0.7 3.6E−5 [14]
Lung cancer vs healthy China Serum NMR 27 24 ↓ 0.5 NA [15]
Progressive disease vs response/breast cancer Singapore Serum NMR 7 22 ↓ NR < 0.05 [32]
Obesity vs Non/colorectal cancer Denmark Serum NMR 78 21 ↓ NR 7.8E−3 [13]
Type 2 diabetes vs healthy Otherb Serum NMR 8 8 ↓ 0.3 < 0.05 [12]
aTumour/normal mucosa
bRhesus monkeys
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high serum formate cancer, amyotrophic lateral sclerosis
and Parkinson’s disease. The latter findings further empha-
sise the need to collect samples from multi-disease cohorts
and the requirement of multinomial classifiers to impute
the different classes based on serum metabolomics or other
biomarkers.
Conclusions
We conclude that circulating formate levels are signifi-
cantly lower in breast cancer, lung cancer and highly obese
patients than in healthy controls. The circulating formate
levels together with those of glucose can be used to stratify
cancer patients, obese individuals and healthy controls.
Further studies are required to determine the relevance of
these observations in the context of other human diseases
and early diagnosis.
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